Chlorpyrifos oxon (CPO), the toxic metabolite of the organophosphorus (OP) insecticide chlorpyrifos, causes developmental neurotoxicity in humans and rodents. CPO is hydrolyzed by paraoxonase-1 (PON1), with protection determined by PON1 levels and the human Q192R polymorphism. To examine how the Q192R polymorphism influences fetal toxicity associated with gestational CPO exposure, we measured enzyme inhibition and fetal-brain gene expression in wild-type (PON1 +/+ ),
its active metabolite chlorpyrifos oxon (CPO) although many other serine hydrolases are also inhibited by CPO. The highly toxic CPO is also formed in the environment through reaction with oxidizing agents and has been detected in foliage (Yuknavage et al., 1997) , air samples (Armstrong et al., 2013a,b) , and vegetables harvested from greenhouses (Vidal et al., 1998) . CPO represented 2-14% of total CPS exposure in air samples (Armstrong et al., 2013b) and CPO residues in green beans and tomatoes were reported to be as high as 0.14-0.21 mg/kg (Vidal et al., 1998) .
Evidence from epidemiologic studies has suggested that OP exposure during pregnancy has adverse effects on birth outcomes and neurodevelopment of children. Prenatal exposure to OP pesticides was negatively associated with child neurobehavioral performance including abnormal reflexes in infants (Engel et al., 2007; Young et al., 2005) , mental and psychomotor development delay in toddlers (Eskenazi et al., 2007; Rauh et al., 2006) , as well as lower IQ and poorer cognitive development in school children (Bouchard et al., 2011; Engel et al., 2011) . Studies using cell cultures and animal models have also indicated that CPS can interfere with normal brain development. CPS and CPO were shown to induce cytotoxicity in both neuronal and glial cells (Monnet-Tschudi et al., 2000) , inhibit DNA synthesis in rat brain (Dam et al., 1998) and in cultures of neurons, glia, and astrocytes (Guizzetti et al., 2005; Qiao et al., 2001) . At the morphological level, CPS and CPO also decreased total axonal length (Howard et al., 2005) . Furthermore, treatment with CPS or CPO altered the expression and function of transcription factors such as AP-1, Sp1, and CREB, which mediate cell replication and differentiation (Crumpton et al., 2000; Schuh et al., 2002) .
These in vitro and in vivo neurotoxic effects were found at doses that are below the threshold of inducing significant AChE inhibition, indicating that the action of CPS/CPO on developing brain may be through different pathways than inhibition of AChE enzymatic activity. It has also been suggested that CPO, with a much higher potency than CPS, may act directly on the morphogenic capability of AChE and on targets such as cell signaling molecules or cytoskeleton proteins (Flaskos, 2012) . A major detoxification pathway of CPO is through hydrolysis by paraoxonase 1 (PON1) as shown by dramatically increased sensitivity to CPO in PON1-knockout mice (Shih et al., 1998) . The PON1 Q192R polymorphism determines catalytic efficiency of the enzyme for hydrolyzing CPO, with the PON1 R192 alloform providing greater protection than the PON1 Q192 alloform against CPO toxicity (Cole et al., 2005; Li et al., 2000) . Epidemiologic studies have demonstrated that both maternal PON1 activity level and the status of her Q192R polymorphism play a role in modulating the association between OP exposure and child neurodevelopment. Maternal PON1 activity level was found to modify the adverse effects of OP exposure on head circumstance of newborns (Berkowitz et al., 2004) and on mental and psychomotor development assessed at 2 years of age (Eskenazi et al., 2010) , whereas the OP-related decrease in perceptual reasoning was found only in children whose mothers were of QQ genotype (Engel et al., 2011) . However, most prenatal OP exposure studies in animals did not address the role of PON1 in OP-related developmental toxicity.
Previously, a toxicogenomic approach has been used to examine the effects of CPS/CPO on gene expression profiles by gestational CPS exposure in mice (Moreira et al., 2010) , by postnatal CPS exposure in neonatal rats (Betancourt et al., 2006; Ray et al., 2010; Slotkin and Seidler, 2007) , by postnatal CPO exposure in neonatal mice (Cole et al., 2011) , and by CPS exposure in adult rats (Stapleton and Chan, 2009) or PC12 cells (Slotkin and Seidler, 2009; Slotkin et al., 2008) . To understand the neurotoxicity of CPO in fetuses following chronic in utero exposure and to examine the importance of the maternal PON1 Q192R polymorphism in protecting fetuses against CPO, we used genome-wide microarrays to measure gene expression changes associated with repeated gestational CPO exposure (GD6 to GD17) in fetal brains of wild type, PON1-knockout, and humanized PON1 transgenic mice that carry either the human R 192 or the Q 192 allele over a PON1-knockout background.
MATERIALS AND METHODS

Animals. PON1 knockout (PON1
−/− ) mice (Shih et al., 1998) and mice expressing either the human PON1 R192 or PON1 Q192 transgene (tgHuPON1 R192 or tgHuPON1 Q192 ) in place of endogenous mouse PON1 (Cole et al., 2003 (Cole et al., , 2005 or PON1 R192 enzyme activity in heparinized saphenous-vein plasma was detected by measuring the rate of hydrolysis of the alloform-neutral substrate, diazoxon, which is alloform-neutral at 0.5 M NaCl (Richter and Furlong, 1999) and has no background activity in PON1 −/− mice (Cole et al., 2003) . Polymerase chain reaction (PCR) based genotyping was used to determine the presence of the transgenes. Mice were housed in specific pathogen-free facilities with a 12-h dark-light cycle and unlimited access to food and water. The animal use protocols used were approved by the Institutional Animal Care and Use Committee at the University of Washington. All animal experiments were carried out in accordance with the National Research Council Guide for the Care and Use of Laboratory Animals, as adopted by the National Institutes of Health.
Chemicals. Chlorpyrifos oxon (CAS 5598-15-2; 98% purity) and diazoxon (CAS 962-58-3; 99% purity) were purchased from Chem Service (West Chester, PA). Acetylthiocholine iodide, butyrylthiochoine iodide, 5,5 -dithio-bis-nitrobenzoic acid, and pnitrophenyl valerate were from Sigma-Aldrich (St Louis, MO). N-Acetyl-L-alanyl-p-nitroanilide was purchased from BACHEM (Torrance, CA). All other analytical grade chemicals were obtained from commercially available sources.
Exposure of mice to chlorpyrifos oxon (CPO). Timed matings of female PON1
+/+ , PON1 −/− , and humanized transgenic mice (tgHuPON1 Q192 and tgHuPON1 R192 ) with males of the same genotype were used to generate pregnant females. The day the copulatory plug was visible was designated as gestational day (GD) 0. The dose of CPO exposure was determined based on the initial body weight of the dam at GD0. Body weights of all mice were measured daily just prior to dosing. Potentially pregnant mice were exposed dermally (1 l/g body weight) to CPO (0, 0.50, 0.75, or 0.85 mg/kg/d) daily from GD6 to GD17. An 8.5 mg/ml stock solution of CPO dissolved in acetone was used to make serial dilutions for exposures. CPO was applied dermally to a shaved portion of the upper back and neck, using a Gilson P200 pipette, then the CPO was allowed to air-dry for 15 s, and the mouse was retained on the wire cage-top for 5 min before returning the mouse to its cage. Control mice received vehicle (acetone, Ͼ 99.9%) alone.
On GD18, 24 hr following the last exposure on GD17, pregnant mice were sacrificed by CO 2 asphyxiation, fetuses were staged (Theiler, 1989) Sample preparation. Red blood cells (RBC) were frozen and thawed on dry ice twice to lyse cells and further diluted 1:80 with 100 mM Tris-HCl, pH 7.5 for assays. Frozen brains were thawed and homogenized in 0.1 M sodium phosphate buffer, pH 8 (6 vol v/w for maternal brains and 1 vol v/w for pooled fetal brains) using a handheld homogenizer (Tissue-Tearor, Cole-Parmer, IL). The crude homogenates were further diluted to 5 mg/ml (maternal samples) or 50 mg/ml (fetal samples) for assay. Frozen livers were homogenized using a Polytron homogenizer (Brinkmann Instruments, Westbury, NY) in 10 mM Tris-HCl, pH 7.5 and 0.25 M sucrose, and then centrifuged at 10,000 × g for 10 min at 4 • C.
Supernatants were centrifuged again at 15,000 × g for 20 min at 4
• C to remove mitochondria. Microsomes were subsequently spun down at 110,000 × g for 30 min at 4
• C using an ultracentrifuge (TL-100, Beckman Coulter Inc). Microsomal pellets were resuspended in 20 mM Tris-HCl, pH 7.5, 0.25 M sucrose, and 0.1 mM CaCl 2 and adjusted to a concentration of 5 mg protein/ml for assays. Protein concentration was determined by the Bradford method using a commercial assay kit (Coomassie Plus Assay Kit, Thermo Scientific Inc).
Enzyme activity assays. All the assays were carried out in triplicate using a SpectraMax Plus microtiter plate reader (Molecular Devices) with 96-well plates. Activities of chlorpyrifos-oxonase (CPOase), butyrylcholinesterase (BChE), and carboxylesterase (CES) were measured in maternal and fetal plasma. AChE activity was measured in maternal and fetal brains. Plasma as well as liver CPOase activities were measured as described previously (Furlong et al., 1989) . Plasma BChE and brain AChE activities were measured as described (Cole et al., 2005) using butyrylthiocholine and acetylthiocholine as substrates, respectively. The initial rates of 5-thio-2-nitrobenzoate formed during the assay were monitored continuously at 412 nm for 4 min (plasma BChE) or 10 min (brain AChE) at room temperature. Plasma CES activity was measured as the rate of hydrolysis of p-nitrophenyl valerate, with the formation of p-nitrophenol monitored at 405 nm for 4 min at room temperature. Acylpeptide hydrolase (APH) activity of RBC was measured with a colorimetric method (Quistad et al., 2005) using N-acetyl-L-alanyl-p-nitroanilide (Ac-Ala-pNA) as substrate. Twenty microliters of diluted (1:80) lysed RBC were added into individual wells containing 100 l of 1.5 mg/ml AcAla-pNA in 100 mM Tris-HCl, pH 7.5. Absorbance from liberated p-nitroaniline was continuously monitored at 405 nm for 4 min at 37
• C.
For all assays, initial linear rates of product formation (mOD/min) for each enzyme were pathlength-corrected and converted to Units per ml (U/ml) or Units per gram (U/g) wet tissue using the respective extinction coefficients: 5-thio-2-nitrobenzoate, 13.6mM 1A and B) . In both NUSE and RLE plots, there were a few arrays that were slight outliers. These arrays were down-weighted in the analysis of variance (ANOVA) model to reduce their impact. An alternative would have been to remove these arrays from the analysis, but as it is difficult to decide on a cutoff for removal, and because doing so would lower the degrees of freedom and decrease the power to detect differences, we used a weighted ANOVA. Supplementary figure 1C shows MA plots comparing the log average of the expression data (horizontal axis; A) to the log difference between a given sample and the median of all samples (vertical axis; M) for each of the 60 array pools. Values were clustered tightly in an oval along the horizontal axis at zero, as would be expected from an ideal data set. In addition, all Affymetrix microarray data passed the manufacturer's QC metrics. For MIAME compliance (Brazma et al., 2001 ) raw data, final processed data, sample and array annotation, and experimental design have been submitted to the NCBI Gene Expression Omnibus (GEO) upon acceptance of the manuscript, and will be available at http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi? acc=GSE58103 (release date: 1 January 2015).
Microarray data analysis: Individual gene analysis. Array data were summarized at the transcript level using a robust multi-array average (RMA) (Irizarry et al., 2003) , followed by fitting a weighted ANOVA model to the data, and comparisons between sample types by fitting empirical Bayes adjusted contrasts. By fitting a weighted ANOVA, we incorporated weights into the model, which allowed us to down-weight arrays that appear to be dis- 
Notes. Data are presented as mean (SE).
Maternal body wt gain (%) = (maternal body wt at GD18-maternal body wt at GD0)/body wt at GD0. Adjusted maternal body wt gain (%) = (maternal body wt at GD18-maternal body wt at GD0-litter wt)/body wt at GD0. *p Ͻ 0.05 as compared with vehicle controls using Student's t-test. All the significant values are in bold.
similar to other arrays of the same type, and increase power of the data set (Ritchie et al., 2006; Smyth, 2004) . Supplementary table 1 lists the comparisons made, and the number of probesets selected at an unadjusted p value of 0.05 and an absolute fold change Ͼ 1.5.
WGCNA.
As an alternative way to analyze these data, we used weighted gene co-expression network analysis (WGCNA), which uses the correlations between expression values to infer gene networks (Langfelder and Horvath, 2008) . To subset the data, we removed all probesets with a standard deviation Ͻ 0.2, which resulted in 1598 probesets. Since there are multiple probesets per gene, and the duplicated probesets generally convey the same information, we further removed any duplicates, resulting in 719 genes. Finally, we subset the samples to just those samples that were treated with 0.75 mg/kg/d CPO. By-gene correlations were then computed, and gene "modules" were detected by clustering the correlation data. Figure 1A shows the clustering dendrogram. Gene clusters were then correlated with phenotypic data (maternal and fetal CPOase, brain AChE, plasma BChE, and plasma CES). Heat maps (Fig. 1B) were generated showing the correlation and correlation p value between each cluster and phenotypic measure. To more closely examine the genes in a given gene module with respect to a given phenotype, module membership, which infers the importance of a gene to the module, was plotted on the horizontal axis, and gene significance, which measures the correlation between a given gene and a phenotypic measure, was plotted on the vertical axis (Fig. 1C) .
Gene set enrichment analysis. Gene set enrichment analysis (GSEA) aims to identify sets of genes that appear to be up-or downregulated. The gene sets that we used for this analysis were from the Broad Institute. The romer function from the Bioconductor limma package (R version 2.15.1) was used to perform GSEA. After completing GSEA, heat maps and data tables were generated for gene sets that had p values Ͻ 0.05. log 2 values. β-Actin expression was not affected by CPO exposure. Microarray data were compared with qPCR data in aggregate using X-Y plots for each contrast (not shown) and also by plotting comparisons of the fold changes of expression measured by qPCR and microarray for selected genes.
RESULTS
Maternal and Fetal PON1 Activity Levels
We determined maternal and fetal plasma PON1 activity levels by measuring rates of CPO hydrolysis. No significant differences in plasma CPOase activity were found between control and treated dams in any of the four genotypes ( (Table 3) .
Maternal and Fetal Body Weights and Birth Outcomes
Our previous studies have shown that PON1 −/− mice are much more sensitive to CPO toxicity than PON1 +/+ and human PON1-transgenic mice (Cole et al., 2005; Shih et al., 1998) . To avoid overt toxicity, pregnant PON1 −/− mice were treated with lower doses of CPO (0.5 and 0.75 mg/kg/day) compared with other genotypes (0.75 and 0.85 mg/kg/day). None of the treated dams showed any cholinergic signs during the 12-day-long treatment from GD6 to GD17. PON1 −/− dams that received 0.75 mg/kg/day of CPO showed significantly lower body weight gain at GD18 (Table 1), and the effect remained unchanged after maternal body weight gain was adjusted for litter weight (litter weight was subtracted from the weight of the dam). Fetuses of the treated (0.75 Both transgenic lines showed genotype-specific but treatment-independent differences in either maternal body weights or birth outcomes. Compared with other genotypes, tgHuPON1 R192 dams had an overall higher resorption rate. The tgHuPON1 Q192 dams had lower adjusted body weight gain, regardless of CPO treatment (Table 1) .
Inhibition of Plasma BChE and CES Activities
All treated dams showed significant inhibition of plasma BChE activity, ranging from 30% to 50% (Fig. 2A) . Gestational exposure to CPO did not cause BChE inhibition in PON1 +/+ or tgHuPON1 R192
fetuses; however, PON1 −/− and tgHuPON1 Q192 fetuses were much more susceptible to CPO toxicity, showing significant decreases in plasma BChE activity (Fig. 2B ). CES is a serine esterase that is abundant in mouse plasma and acts as a scavenger for OP compounds. CPO treatment caused moderate inhibition of plasma CES in all dams except tgHuPON1 Q192 mice (Fig. 3A) . Plasma CES activity in PON1 −/− fetuses was also significantly inhibited by CPO exposure (Fig. 3B) .
Inhibition of Brain AChE
Maternal brain AChE activity of PON1 −/− , tgHuPON1 R192 , and tgHuPON1 Q192 mice was significantly inhibited by approximately 50% following repeated CPO exposure (Fig. 4A) . No inhibition of brain AChE activity was found in PON1 +/+ dams (Fig. 4A ), even though they showed significant reduction of both plasma BChE ( Fig. 2A) and CES activity (Fig. 3A) . Effect on fetal brain AChE was found in PON1 −/− fetuses only (Fig. 4B) . Although tgHuPON1 R192
and tgHuPON1 Q192 dams showed increased sensitivity to CPO toxicity compared with PON1 +/+ dams, their fetuses were well protected from CPO exposure in terms of brain AChE activity (Fig.  4B) .
Inhibition of Erythrocyte Acylpeptide Hydrolase
APH is a cytosolic enzyme found in a variety of tissues including brain, liver, and RBC. As a serine protease, APH of RBC is also a target enzyme for OP compounds and has been suggested to serve as a biomarker for OP exposure (Quistad et al., 2005) . We found that compared with other plasma target enzymes such as BChE and CES, APH of RBC was the most sensitive biomarker in dams following repeated exposure to CPO (Fig. 5A) . Further, inhibition of APH activity by CPO exposure was genotype-dependent, with PON1 −/− being the most sensitive, followed by tgHuPON1 Q192 , tgHuPON1 R192 , and PON1 +/+ . However, no inhibition of APH activity was found in fetuses (Fig. 5B) .
Gene Expression in the Fetal Brain
Gene expression in the brains of GD18 fetuses was measured using Affymetrix Mouse Gene 1.0 ST microarrays, followed by analysis of the expression data at the transcript level using RMA and a weighted ANOVA, with comparisons made among sample types by fitting empirical Bayes adjusted contrasts. Supplementary table 1 lists the probesets with unadjusted p values less than 0.05 and an absolute fold change of 1.5 or greater for the specific comparisons made between genotypes and treatment groups. Despite using an unadjusted p value of 0.05 as a measure of significance, there were still very few differentially expressed probesets for any of the contrasts, and many of the probesets did not correspond to known functionally annotated genes. Indeed,
FIG. 2. Plasma BChE activity in dams (A) and fetuses (B). Pregnant PON1 +/+ ,
tgHuPON1R192, and tgHuPON1Q192 mice were exposed to 0.75 mg/kg/day CPO, 0.85 mg/kg/day CPO, or vehicle alone from GD6 to GD17. PON1 −/− dams were treated in the same manner but received lower doses of CPO of 0.5 mg/kg/day or 0.75 mg/kg/day. Dose-dependent plasma BChE inhibition was found in PON1 −/− dams but only the group that received 0.75 mg/kg/day CPO was presented here. Plasma BChE activity was determined at GD18, 24 h after the last dosing of CPO. Data are presented as mean ± SE. N = 5-10 for each treatment group. *p Ͻ 0.05 and **p Ͻ 0.01 as compared with vehicle control.
no known genes were differentially expressed in the treated versus control comparisons of PON1 +/+ or PON1 −/− mice, and only one known gene (triadin) was affected in the tgHuPON1Q 192 comparisons. Furthermore, PCA did not reveal any particular grouping of data according to genotype or treatment (not shown). This may reflect either a high technical or biological variability, which may be masking true differences, or alternatively there may be many very small changes in gene expression that result in a visible phenotypic difference. To address the latter possibility, GSEA was used to detect statistically significant changes in expression for groups of genes in their entirety (rather than individual genes). To determine whether the phenotypic differences in maternal or fetal enzyme inhibition correlated with any particular groups of genes, WGCNA was performed.
Weighted Gene Coexpression Analysis
WGCNA uses the correlations between expression values to infer gene networks (Langfelder and Horvath, 2008) . Figure  1A shows the clustering dendrogram generated by the initial WGCNA analysis. The colored bars at the bottom of the plot indicate the cluster boundaries for the five clusters (blue, brown,
FIG. 3. Plasma CES activity in dams (A) and fetuses (B). Pregnant PON1 +/+ ,
tgHuPON1R192, and tgHuPON1Q192 mice were exposed to 0.75 mg/kg/day CPO, 0.85 mg/kg/day CPO, or vehicle alone from GD6 to GD17. PON1 −/− dams were treated in the same manner but received lower doses of CPO at 0.5 mg/kg/day and 0.75 mg/kg/day. Plasma CES activity was determined at GD18, using p-nitrophenyl valerate as substrate. Data are presented as mean ± SE. N = 5-10 for each treatment group. *p Ͻ 0.05 and **p Ͻ 0.01 as compared with vehicle control.
green, turquoise, and yellow) that were identified by this analysis. The gray band covers those genes that do not cluster. Supplementary table 2 lists the genes (blue, 401 genes; brown, 160 genes; green, 39 genes; turquoise, 225 genes; yellow, 45 genes; gray, 74 genes) that comprise each of these clusters. The gene clusters were then correlated with phenotypic data (maternal and fetal CPOase, brain AChE, plasma BChE, and plasma CES). Figure 1B shows a heat map illustrating the correlation and correlation p value between each cluster and phenotypic measure. The most notable pattern was the negative correlation between maternal brain AChE and the green gene module. In addition, there was a positive correlation between maternal plasma CPOase and the green module. Correlation values with phenotypic data for maternal and fetal brain AChE and plasma BChE are listed in Supplementary table 2 for each gene in the six clusters. To more closely examine the genes in the green gene module with respect to a given phenotype, Figure 1C plots module membership, which infers the importance of a gene to the module, versus gene significance, which measures the correlation between a given gene and the phenotypic measure, in this case maternal brain AChE. The correlation between these measures was quite high, and significant. The genes at the top right of the plot are those that are highly correlated to both maternal brain
FIG. 4. Brain AChE activity in dams (A) and fetuses (B). Pregnant PON1 +/+ ,
tgHuPON1R192, and tgHuPON1Q192 mice were exposed to 0.75 mg/kg/day CPO, 0.85 mg/kg/day CPO, or vehicle alone from GD6 to GD17. PON1 −/− dams were treated in the same manner but received lower doses of CPO at 0.5 mg/kg/day and 0.75 mg/kg/day. Dose-dependent brain AChE inhibition was found in PON1 −/− dams but only the group that received 0.75 mg/kg/day CPO was presented here. Brain AChE activity was determined at GD18 as described in the Materials and Methods section. Data are presented as mean ± SE. N = 5-10 for each treatment group. *p Ͻ 0.05 and **p Ͻ 0.01 as compared with vehicle control.
AChE levels, as well as being "hub" genes in the green module, with high inter-gene correlations with a preponderance of the other genes in this gene module. Interestingly, homeobox (HOX) genes comprised a large number of the genes in the green module, and HOX gene expression was negatively correlated with maternal brain AChE activity. Thus, AChE inhibition in the maternal brain was associated with an increase in HOX gene expression (and the expression of some other green module genes) in the brains of that dam's fetuses following repeated gestational CPO exposure. Figure 6 shows heat maps of six selected gene sets identified by GSEA that were significantly enriched (p Ͻ 0.05) in the brains of tgHuPON1 Q192 offspring treated with 0.85 mg/kg/d of CPO compared with vehicle, in comparison with the heat maps of the same gene sets from the brains of tgHuPON1 R192 offspring. All of the heat maps showed stronger effects in terms of gene expression differences in the tgHuPON1 Q192 offspring compared with the tgHuPON1 R192 offspring. Among the six gene sets, one Reactome gene set (GABA A Receptor Reaction) was also significantly enriched for the direct between-genotype comparison of tgHuPON1 Q192 versus tgHuPON1 R192 offspring exposed to 0.85 mg/kg/d CPO. 
Gene Set Enrichment Analysis
RT-PCR Confirmation
Thirty genes were selected for validation by qPCR based on the high dose (0.85 mg/kg/d) versus control contrast in tgHuPON1 Q192 mice. About two-thirds of these were based on gene sets that were significant in aggregate, and the other one-third were selected based on p value and fold change from the original univariate comparisons. Specific genes selected for confirmation by qPCR are listed in Table 4 . Samples were analyzed with a Fluidigm-based qPCR assay, normalizing the copy number data to the housekeeping gene, β-actin. Figure 7 shows the log 2 fold change of expression, as measured by microarray (light bars) and qPCR (dark bars), of the genes (Amacr, Atp6v1f, Cox18, Creld2, Derl2, Gabrb1, Grm8, Hexb, Hspa5, Manf, Med7, Pon2, Shox2, Urod) for which microarray expression values were validated by qPCR. These genes showed good correspondence between the microarray and qPCR data, with log 2 fold-change values ranging from approximately + 0.2 to + 0.5.
DISCUSSION
This study shows that gestational exposure to CPO causes cholinesterase (ChE) inhibition in fetuses and alterations of gene expression in fetal brain. These effects are modulated by maternal PON1 status, with PON1 −/− fetuses being the most susceptible to CPO toxicity and tgHuPON1 Q192 fetuses being more sensitive to CPO than tgHuPON1 R192 fetuses. This is the first study using a humanized transgenic mouse model to demonstrate that maternal PON1 activity levels as well as the genotype of maternal PON1 Q192R polymorphism modulate the toxic effects of OP exposure during pregnancy. In this study, dams were exposed to the toxic oxon CPO, instead of the parent compound CPS. However, given the presence of CPO in most exposures including air samples and crops (Armstrong et al., 2013a,b; Vidal et al., 1998) , the importance of direct exposure to CPO cannot be ignored, even for the general population. The doses of CPO used in the present study caused only moderate or no inhibition of maternal ChE in PON1 +/+ mice but had severe effects in genetically compromised PON1 −/− and tgHuPON1 Q192 mice, reflecting the nature of genetic variability and susceptibility in humans. Our results are in agreement with previous epidemiologic studies that reported a positive association between developmental delay in children and in utero exposure to OP insecticides, particularly in children whose mothers were homozygous for the Q 192 allele or had low serum PON1 activity levels (Berkowitz et al., 2004; Engel et al., 2011; Eskenazi et al., 2010) . Plasma PON1 activity levels are extremely low in fetuses (Table 2), indicating that fetuses have little ability to hydrolyze CPO and must depend on maternal biotransformation enzymes to detoxify the compound before it reaches the fetus. It is known that fetuses recover rapidly from the inhibitory effect of CPO on brain AChE and plasma BChE due to the rapid de novo synthesis of these enzymes in the fetus (Ashry et al., 2002) . Despite this rapid recovery, we still found significant inhibition of plasma BChE in both PON −/− and tgHuPON1 Q192 fetuses and inhibition of brain AChE in PON −/− fetuses. These findings suggest that without the protection afforded by a catalytically efficient maternal PON1, i.e., the PON1 R192 alloform, fetuses cannot recover from repeated exposure to CPO. A previous study in C57BL/6 mice with a similar design of gestational exposure (GD6 to GD17, s.c.) but using the parent compound CPS also showed that fetuses were more resistant to CPS toxicity than dams (Moreira et al., 2010) .
In that study, CPS doses of 10-15 mg/kg/d inhibited maternal and fetal brain AChE by 40-60% and 20-30%, respectively. In contrast, CPO doses of 0.75-0.85 mg/kg/d in the current study inhibited maternal brain AChE in the humanized transgenic mice by about the same amount (50-60%), but there was no inhibition of fetal brain AChE. This increased sensitivity of fetal brain AChE to CPS compared with CPO is likely due to rapid detoxication of CPO in the maternal plasma, whereas CPS may undergo more localized biotransformation to CPO in the fetus or placenta. Compared with PON1 +/+ dams, tgHuPON1 R192 and tgHuPON1 Q192 dams had relatively low levels of liver PON1 activity (Table 3) . In this study, it appears that maternal liver PON1 may not play a significant role in modulating CPO toxicity in the fetus because even with very low liver PON1 activity levels, tgHuPON1 R192 dams offered sufficient protection for their fetuses. In addition to plasma PON1, maternal plasma BChE and CES may also provide some protection against CPO by covalently binding CPO. An interesting finding of this study is that RBC APH seemed to be a more sensitive biomarker in dams than plasma BChE following repeated CPO exposure. In the dams, RBC APH was inhibited to a greater extent than plasma BChE in all genotypes of mice. For example, when tgHuPON1 Q192 dams were exposed to 0.85 mg/kg/d of CPO for 12 days, their RBC APH was inhibited to 13% of control whereas plasma BChE was 72% of control. The much higher inhibition found in RBC APH could be due to a longer half-life of RBC APH than plasma BChE (33 days vs. 11 days). The strong inhibitory effect on APH is of great interest because brain APH was found to function in cleavage of ␤-amyloid peptide (Yamin et al., 2007) and modulation of synaptic plasticity (Olmos et al., 2009) , and this mechanism may be relevant to the effects of CPO exposure on expression of gene sets related to neurodegenerative disease and neurotransmission. It has been suggested that RBC APH can be used as an alternative biomarker for OP exposure (Quistad et al., 2005) and our related study also shows a good correlation of RBC APH inhibition with diazinonoxon toxicity in brain and diaphragm (Li et al., in preparation) .
Another interesting finding is that compared with other genotypes, tgHuPON1 R192 dams tended to have a high resorption rate (number of resorptions per implant) regardless of CPO exposure (Table 1) . It is unclear why tgHuPON1 R192 mice had a relatively high resorption rate. However, a recent epidemiologic For genes selected on the basis of GSEA, the gene set listed is that with the most significant enrichment.
study showed that the risk of miscarriage by PON1 R192 homozygous women was 2.2 times higher than women of QR and QQ genotypes (Blanco-Munoz et al., 2013) . What possible explanation is behind the high rate of resorption/miscarriage found to be associated with the PON1 R192 allele is worthy of additional studies.
The microarray data reported in the current study are consistent with increased sensitivity to CPO of individuals carrying the tgHuPON1 Q192 alloform. As in our previous study that examined gene expression following neonatal exposure to CPO (Cole et al., 2011) , individual gene analysis revealed only a small number of affected genes. This was not surprising given the low doses of CPO used for the study and signal dilution due to the use of the entire fetal brain and pooling of the samples, therefore, WGCNA and GSEA were used as more sensitive methods to investigate the subtle gene expression effects following gestational CPO exposure.
WGCNA allowed anchoring of the gene expression effects to the phenotypic data on biomarker inhibition and plasma PON1 levels. WGCNA identified six gene modules based on clustering of the correlations among their fetal-brain expression values. The "green" module, which correlated highly with maternal plasma CPOase activity and negatively with maternal brain AChE activity, had a large representation (11/39 genes) of HOX genes, suggesting effects of gestational CPO exposure on axial patterning during development that are correlated with the ability of maternal PON1 levels to protect against brain AChE inhibition.
Due to the smaller effect sizes associated with low-level CPO exposure, GSEA was used to evaluate the expression of gene sets, using 14 different categories from the BROAD Institute (http://www.broadinstitute.org/gsea/msigdb/index.jsp). In all of the categories, there were more significantly enriched gene sets in the fetuses of tgHuPON1 Q192 dams compared with those of tgHuPON1 R192 dams, consistent with the lower catalytic efficiency of the PON1 Q192 alloform for hydrolyzing CPO. Supplementary table 3 lists a large number of gene sets in several different categories that were enriched in the tgHuPON1 Q192 mice following CPO exposure. In addition to the gene sets whose heat maps are shown in Figure 6 (GABA-A receptor activation, lipid metabolism, protein export, endoplasmic reticulum, hydrogen ion transporter activity, and insulin receptor signaling), gene sets identified include those related to the mitochondrial respiratory chain, the cell cycle, vesicle membranes, neurotransmission by glutamate receptors, and Wnt signaling, among many others. To our knowledge, there have only been two studies examining gene expression in the brains of mice following developmental OP exposure (Cole et al., 2011; Moreira et al., 2010) , and both offer an interesting comparison with the current study. Moreira et al. (2010) exposed C57BL/6 mice to five different doses of CPS over the same gestational period used in the current study, producing similar levels of maternal brain AChE inhibition. They also measured gene expression in pooled GD18 fetal brains using Affymetrix Mouse Genome arrays. Some of the GO Biological Process categories they identified were similar to the gene sets identified in the current study, including GO categories related to the cell cycle, lipid biosynthesis and transport, vesiclemediated transport, neurotransmission, Wnt and MAPK signaling, ER-related signaling, growth regulation, and nervous system development, as well as KEGG pathways that included neurodegenerative diseases and insulin signaling (Moreira et al., 2010) . Nervous system development, synaptic transmission, and Wnt signaling were also identified as relevant pathways in the adult rat forebrain by Stapleton and Chan (2009) . Wnt signaling was also affected in neonatal rat (Slotkin et al., 2008) . The only other study to assess CPO effects on gene expression was by Cole et al. (2011) in which mice were exposed to CPO neonatally and gene expression was measured in the cerebellum at PND22. Some of the gene sets identified in the postnatal study were similar to the ones recognized in the current study, including those related to the mitochondrial respiratory chain, synaptic transmission, insulin receptor signaling, MAPK signaling, lipid metabolism, and oxidoreductase activity (Cole et al., 2011) . As in the current study, Cole et al. (2011) found that mice expressing tgHuPON1 Q192 were more sensitive to CPO-related effects on gene expression than mice expressing tgHuPON1 R192 . This is the first and the only study in an animal model that addresses the differential susceptibility to CPO afforded by the tgHuPON1 Q192R polymorphism during pregnancy. The data show that maternal PON1 status modulates the effects of repeated gestational CPO exposure on enzyme activities in the dam and fetuses, and gene expression measured in the GD18 fetal brain. Consistent with previous studies both in adults and during development (Cole et al., 2005, ; Li et al., 2000) , the tgHuPON1 Q192 alloform was less protective than tgHuPON1 R192 against CPO exposure. It must be noted that in the current study, dams of the same genotype and treatment group expressed similar PON1 levels; however, plasma PON1 activity levels vary by at least 13-fold among individuals (Furlong et al., 2006) and therefore it is important to also measure PON1 activity within each PON1 192 genotype in epidemiologic studies.
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